» Articles » PMID: 36751300

The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study

Overview
Journal TH Open
Publisher Thieme
Date 2023 Feb 8
PMID 36751300
Authors
Affiliations
Soon will be listed here.
Abstract

 Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic options for medical and surgical oncology patients presenting to health care settings in Saudi Arabia.  The present consensus was developed in concordance with the modified Delphi-based approach, which incorporates a face-to-face meeting between two voting rounds to gain experts' feedback on the proposed statements. All experts were either oncologists, hematologists, or hemato-oncologist with an active clinical and research profile in hemato-oncology.  The experts highlighted that the comparatively high incidence of inherited thrombophilia among the Saudi population may account for a higher CT burden in the Kingdom than in other parts of the world. However, due to the lack of literature that assesses CT in Saudi Arabia, primary venous thromboembolism prophylaxis should be tailored according to a valid risk assessment of cancer patients and should be implemented in routine practice. For hospitalized medical oncology patients, the experts agreed that prophylaxis with low-molecular-weight heparin (LMWH) should be offered, regardless of the presence of acute illness. For ambulatory medical oncology patients, LMWH or direct oral anticoagulants (DOACs) prophylaxis should be offered for high-risk patients. Concerning surgical patients, they agreed that all oncology patients undergoing surgery should be offered thromboprophylaxis. In terms of secondary prophylaxis, the experts recommended continuing a prophylactic dose of anticoagulant (LMWH or DOAC), for an appropriate period depending on the cancer type and stage. Finally, they also provided a set of statements on management of CT in Saudi Arabia.  The present modified Delphi-based study combined the best available evidence and clinical experience with the current health care policies and settings in Saudi Arabia to build a consensus statement on the epidemiology, prevention, and management of CT.

Citing Articles

The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.

Bazarbashi S, El Zawahry H, Owaidah T, AlBader M, Warsi A, Marashi M J Blood Med. 2024; 15:171-189.

PMID: 38686358 PMC: 11057512. DOI: 10.2147/JBM.S411520.

References
1.
Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

2.
Khorana A, Otten H, Zwicker J, Connolly G, Bancel D, Pabinger I . Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014; 12(11):1928-31. DOI: 10.1111/jth.12725. View

3.
Kakkar V, Balibrea J, Martinez-Gonzalez J, Prandoni P . Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010; 8(6):1223-9. DOI: 10.1111/j.1538-7836.2010.03892.x. View

4.
Carrier M, Khorana A, Moretto P, Le Gal G, Karp R, Zwicker J . Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med. 2014; 127(1):82-6.e1. DOI: 10.1016/j.amjmed.2013.09.015. View

5.
Vormittag R, Simanek R, Ay C, Dunkler D, Quehenberger P, Marosi C . High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol. 2009; 29(12):2176-81. DOI: 10.1161/ATVBAHA.109.190827. View